Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin

A Guberman1

  • 1Division of Neurology, Ottawa General Hospital, ON.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Vigabatrin (VGB) effectively treats complex partial seizures and infantile spasms by inhibiting GABA transaminase. While generally well-tolerated, it may cause behavioral side effects in a small percentage of patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro developmental competence of bovine demi-embryos generated by blastomere separation and blastocyst bisection.

Reproduction in domestic animals = Zuchthygiene·2024
Same author

Fibrous dysplasia of the skull base presenting acutely in an adult.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2006
Same author

Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.

Seizure·2006
Same author

Low-dose topiramate in adults with treatment-resistant partial-onset seizures.

Acta neurologica Scandinavica·2002
Same author

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.

Seizure·2002
Same author

Screening for and characterization of phospholipase A1 hypersecretory mutants of Tetrahymena thermophila.

Applied microbiology and biotechnology·2000
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Diagnostic efficacy, costs, and safety of portable ultra-low field MRI in brain imaging: a systematic review.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years' Duration: Pre- versus Post-Motor Period.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Epileptology

Background:

  • Vigabatrin (VGB) is an antiepileptic drug with a defined mechanism of action.
  • It inhibits GABA transaminase, increasing brain GABA levels.
  • Extensive global clinical experience exists with over 150,000 patients.

Purpose of the Study:

  • To review the efficacy and safety of Vigabatrin.
  • To discuss its pharmacokinetic profile and dosing.
  • To outline its adverse effects and current role in epilepsy treatment.

Main Methods:

  • Review of controlled studies (short and long-term).
  • Analysis of worldwide post-marketing data.
  • Pharmacokinetic and adverse event profiling.

Related Experiment Videos

Main Results:

  • VGB is effective as an add-on therapy for complex partial seizures and infantile spasms.
  • Favorable pharmacokinetics include low protein binding, renal excretion, and long half-life enabling once or twice daily dosing.
  • Generally well-tolerated with minimal cognitive effects, but 2-4% experience behavioral side effects (agitation, irritability, depression, psychosis).

Conclusions:

  • Vigabatrin is an established treatment for specific seizure types, particularly infantile spasms and complex partial seizures.
  • Its pharmacokinetic profile supports convenient dosing.
  • Monitoring for behavioral side effects is crucial, and its role in other childhood epilepsies requires further definition.